Evidence map›Paper›PMID 21816955›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2011

Molecular analysis and structure-activity relationship modeling of the substrate/inhibitor interaction site of plasma membrane monoamine transporter.

Horace T B Ho, Yongmei Pan, Zhiyi Cui, Haichuan Duan, Peter W Swaan, Joanne Wang

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Brain Plasma Membrane Monoamine Transporter in Health and Disease.Handbook of experimental pharmacology · 2021
    Article
  3. Review
  4. Potent inhibition of human organic cation transporter 2 (hOCT2) by β-carboline alkaloids.Xenobiotica; the fate of foreign compounds in biological systems · 2017
    Article
  5. Equilibrative nucleoside transporters-A review.Nucleosides, nucleotides & nucleic acids · 2017
    Review
  6. Review
  7. Review
  8. Potent and Selective Inhibition of Plasma Membrane Monoamine Transporter by HIV Protease Inhibitors.Drug metabolism and disposition: the biological fate of chemicals · 2015
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Horace T B HoDepartment of Pharmaceutics, University of Washington, H272J Health Sciences Building, Seattle, WA 98195, USA.
Yongmei Pan
Zhiyi Cui
Haichuan Duan
Peter W Swaan
Joanne Wang
University of Washington · US

Funding

The plasma membrane monoamine transporter (PMAT): expression and role in mIBG disposition in neuroblastomaR01GM066233 · NIGMS · UNIVERSITY OF WASHINGTON · PI WANG, JOANNE · 2002 to 2020
$5.1M
Structural Biology of the Apical Bile Acid Transporter.R01DK061425 · NIDDK · UNIVERSITY OF MARYLAND BALTIMORE · PI SWAAN, PETER W · 2003 to 2020
$4.6M
NIDDK NIH HHS R01 DK061425NIGMS NIH HHS GM066233NIGMS NIH HHS GM066233-07S1NIGMS NIH HHS R01 GM066233
6 · The paper itself

Abstract

Plasma membrane monoamine transporter (PMAT) is a new polyspecific transporter that interacts with a wide range of structurally diverse organic cations. To map the physicochemical descriptors of cationic compounds that allow interaction with PMAT, we systematically analyzed the interactions between PMAT and three series of structural analogs of known organic cation substrates including phenylalkylamines, n-tetraalkylammonium (n-TAA) compounds, and β-carbolines. Our results showed that phenylalkylamines with a distance between the aromatic ring and the positively charged amine nitrogen atom of ∼6.4 Å confer optimal interactions with PMAT, whereas studies with n-TAA compounds revealed an excellent correlation between IC(50) values and hydrophobicity. The five β-carbolines that we tested, which possess a pyridinium-like structure and are structurally related to the neurotoxin 1-methyl-4-phenylpyridinium, inhibited PMAT with high affinity (IC(50) values of 39.1-65.5 μM). Cytotoxicity analysis further showed that cells expressing PMAT are 14- to 15-fold more sensitive to harmalan and norharmanium, suggesting that these two β-carbolines are also transportable substrates of PMAT. We then used computer-aided modeling to generate qualitative and quantitative three-dimensional pharmacophore models on the basis of 23 previously reported and currently identified PMAT inhibitors and noninhibitors. These models are characterized by a hydrogen bond donor and two to three hydrophobic features with distances between the hydrogen bond donor and hydrophobic features ranging between 5.20 and 7.02 Å. The consistency between the mapping results and observed PMAT affinity of a set of test compounds indicates that the models performed well in inhibitor prediction and could be useful for future virtual screening of new PMAT inhibitors.

Indexed as

Aniline CompoundsAnimalsBenzene DerivativesCarbolinesCell LineCloning, MolecularDogsDrug Evaluation, PreclinicalEquilibrative Nucleoside Transport ProteinsHEK293 CellsHumansInhibitory Concentration 50Models, MolecularMolecular ConformationQuaternary Ammonium CompoundsStructure-Activity RelationshipAniline CompoundsBenzene DerivativesCarbolinesEquilibrative Nucleoside Transport ProteinsharmalanQuaternary Ammonium CompoundsSLC29A4 protein, human

Identifiers

PMID21816955
PMCPMC3199987
OpenAlexW2152007607

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.